Some industry groups have begun voicing their concerns that proposed tariffs could have a negative effect on the production of generics and biosimilars, and may increase the cost of these products.
Recently, President Donald Trump proposed tariffs on thousands of Chinese-manufactured products. According to the list produced by the United States Trade Representative (UTSR), which comprises more than 1300 Chinese products worth about $50 billion each year, some of these products are key ingredients used by drug makers.
A tariff of 25% would be placed on products from the automobile, aerospace, and information technology sphere, as well as the raw ingredients for drugs such as insulin, epinephrine, antibiotics, vaccines, and immunological products as well as some medical devices.
Some industry groups have begun voicing their concerns that these tariffs could have a negative effect on the production of generics and biosimilars, and may increase the cost of these products.
“We are assessing the proposed tariff list of pharmaceutical ingredients and products by the USTR and its possible impact on manufacturing costs for affordable, FDA-approved generic and biosimilar medicines. We are concerned that the proposed tariffs may lead to increased costs of manufacturing for generics and biosimilars and thus high prescription drug prices for patients in the United States,” said Jeffrey K. Francer, senior vice president and general counsel for the Association for Accessible Medicines (AAM) in a statement.
“In 2016, our member companies produced over 61 billion doses of generic and biosimilar medicines in the United States. AAM will maintain a dialogue with USTR to ensure continued patient access to generic and biosimilar medicines,” added Francer.
More than 80% of the ingredients used in the production of drugs prescribed to patients in the United States are produced outside of the country, according to the FDA. In fact, China, together with India, accounts for the production of so many ingredients that the FDA has referred to China as, “a major provider” of these key products.
In a recent interview, Novartis’ CEO, Vasant Narasimhan, MD, also voiced his concern. “I think it would only damage the global economy and obviously impact companies like us—we have manufacturing sites around the world, including in China and the United States. And we need to be able to run our global supply chains in a stable way.”
The Trump administration is requesting public comment on the USTR list until May 11, 2018, and will hold a public hearing on May 15 in Washington, DC.
Following the hearing, companies will have until May 22, 2018, to file any rebuttals.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.